Show simple item record

dc.contributor.authorVargas M.
dc.contributor.authorBustamante C.
dc.contributor.authorVillarraga EA.
dc.date.accessioned2019-07-18T13:54:06Z
dc.date.available2019-07-18T13:54:06Z
dc.date.issued2015
dc.identifier.citationVargas M, Bustamante C, Villarraga EA (2015) Fed and Fasting Bioequivalence Study for Two Formulations of Bosentan 125 Mg Tablets in Healthy Colombian People. J Bioequiv Availab 7: 210-215. doi:10.4172/jbb.1000242es_CO
dc.identifier.issn0975-0851
dc.identifier.otherhttps://www.longdom.org/open-access/fed-and-fasting-bioequivalence-study-for-two-formulations-of-bosentan125-mg-tablets-in-healthy-colombian-people-jbb-1000242.pdf
dc.identifier.urihttp://hdl.handle.net/10818/36217
dc.description6 páginases_CO
dc.description.abstractThis is a pharmacokinetic study of two formulations containing Bosentan 125 mg, in order to compare the bioavailability between the Test product (Bosentan produced by Tecnoquímicas S.A. laboratory, Colombia) and the Reference product (Tracleer® produced by Actelion Pharmaceuticals) in fasting and fed conditions, in order to state the bioequivalence between them. With this purpose, an open label, four periods, two randomized sequences, crossover, with single pre- and fed 125 mg dose study was performed in 30 healthy volunteers, with an 8-day washout period between each period and a collection of 14 plasma samples between 0 and 24 hours. Identification and evaluation of Bosentan in plasma was carried out by ultra-high-performance liquid chromatography-tandem mass spectrometry UHPLC/MS/MS as analytical method. Based on the European and FDA bioequivalence research guidelines, the Confidence Interval (CI) falls within the allowed ranges for the Bioequivalence and Interchangeability Statement of the Tecnoquímicas S.A. product with the Reference product. Both formulations had similar pharmacokinetic parameters in each studied condition, fed and fasted. Moreover, an increase in the amount of active pharmaceutical ingredient is evident in fed conditions.es_CO
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherJournal of J Bioequivalence & Bioavailabilityes_CO
dc.relation.ispartofseriesJ Bioequiv Availab 2015, 7:5
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subjectBioequivalencees_CO
dc.subjectBosentanes_CO
dc.subjectPulmonary hypertensiones_CO
dc.subjectEndothelines_CO
dc.subjectPharmacokineticses_CO
dc.titleFed and Fasting Bioequivalence Study for Two Formulations of Bosentan 125 Mg Tablets in Healthy Colombian Peoplees_CO
dc.typearticlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.4172/jbb.1000242


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcept where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International